Literature DB >> 14715539

Magnitude of serum and intestinal antibody responses induced by sequential replicating and nonreplicating rotavirus vaccines in gnotobiotic pigs and correlation with protection.

Marli S P Azevedo1, Lijuan Yuan, Cristiana Iosef, Kyeong-Ok Chang, Yunjeong Kim, Trang Van Nguyen, Linda J Saif.   

Abstract

A sequential mucosal prime-boost vaccine regimen of oral attenuated (Att) human rotavirus (HRV) priming followed by intranasal (i.n.) boosting with rotavirus protein VP2 and VP6 rotavirus-like particles (2/6-VLPs) has previously been shown to be effective for induction of intestinal antibody-secreting cell (ASC) responses and protection in gnotobiotic pigs. Because serum or fecal antibody titers, but not intestinal ASC responses, can be used as potential markers of protective immunity in clinical vaccine trials, we determined the serum and intestinal antibody responses to this prime-boost rotavirus vaccine regimen and the correlations with protection. Gnotobiotic pigs were vaccinated with one of the two sequential vaccines: AttHRV orally preceding 2/6-VLP (VLP2x) vaccination (AttHRV/VLP2x) or following VLP2x vaccination (VLP2x/AttHRV) given i.n. with a mutant Escherichia coli heat-labile toxin (mLT) as adjuvant. These vaccines were also compared with three i.n. doses of VLP+mLT (VLP3x) and one and three oral doses of AttHRV (AttHRV1x and AttHRV3x, respectively). Before challenge all pigs in the AttHRV/VLP2x group seroconverted to positivity for serum immunoglobulin A (IgA) antibodies. The pigs in this group also had significantly higher (P < 0.05) intestinal IgA antibody titers pre- and postchallenge and IgG antibody titers postchallenge compared to those in the other groups. Statistical analyses of the correlations between serum IgM, IgA, IgG, and virus-neutralizing antibody titers and protection demonstrated that each of these was an indicator of protective immunity induced by the AttHRV3x and the AttHRV/VLP2x regimens. However, only IgA and not IgM or IgG antibody titers in serum were highly correlated (R2 = 0.89; P < 0.001) with the corresponding isotype antibody (IgA) titers in the intestines among all the vaccinated groups, indicating that the IgA antibody titer is probably the most reliable indicator of protection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14715539      PMCID: PMC321356          DOI: 10.1128/cdli.11.1.12-20.2004

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  43 in total

Review 1.  A road less travelled: large animal models in immunological research.

Authors:  Wayne R Hein; Philip J Griebel
Journal:  Nat Rev Immunol       Date:  2003-01       Impact factor: 53.106

2.  Rotavirus vaccine shows promise.

Authors:  Claudia Orellana
Journal:  Lancet Infect Dis       Date:  2003-07       Impact factor: 25.071

Review 3.  The role of serum antibodies in the protection against rotavirus disease: an overview.

Authors:  Baoming Jiang; Jon R Gentsch; Roger I Glass
Journal:  Clin Infect Dis       Date:  2002-04-22       Impact factor: 9.079

4.  Comparison of mucosal and systemic humoral immune responses and subsequent protection in mice orally inoculated with a homologous or a heterologous rotavirus.

Authors:  N Feng; J W Burns; L Bracy; H B Greenberg
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

5.  Early phase II trial of human rotavirus vaccine candidate RV3.

Authors:  Graeme L Barnes; Jennifer S Lund; Susan V Mitchell; Leonie De Bruyn; Leone Piggford; Arnold L Smith; Janine Furmedge; Paul J Masendycz; Helen C Bugg; Nada Bogdanovic-Sakran; John B Carlin; Ruth F Bishop
Journal:  Vaccine       Date:  2002-07-26       Impact factor: 3.641

6.  Serum IgA immune response to individual rotavirus polypeptides in young children with rotavirus infection.

Authors:  K Johansen; L Granqvist; K Karlén; G Stintzing; I Uhnoo; L Svensson
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

7.  Role of coproantibody in clinical protection of children during reinfection with rotavirus.

Authors:  B S Coulson; K Grimwood; I L Hudson; G L Barnes; R F Bishop
Journal:  J Clin Microbiol       Date:  1992-07       Impact factor: 5.948

8.  CD4 T cells are the only lymphocytes needed to protect mice against rotavirus shedding after intranasal immunization with a chimeric VP6 protein and the adjuvant LT(R192G).

Authors:  Monica M McNeal; John L VanCott; Anthony H C Choi; Matili Basu; Jason A Flint; Susan C Stone; John D Clements; Richard L Ward
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

9.  Protective immunity and antibody-secreting cell responses elicited by combined oral attenuated Wa human rotavirus and intranasal Wa 2/6-VLPs with mutant Escherichia coli heat-labile toxin in gnotobiotic pigs.

Authors:  L Yuan; C Iosef; M S Azevedo; Y Kim; Y Qian; A Geyer; T V Nguyen; K O Chang; L J Saif
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

Review 10.  Induction of mucosal immune responses and protection against enteric viruses: rotavirus infection of gnotobiotic pigs as a model.

Authors:  Lijuan Yuan; Linda J Saif
Journal:  Vet Immunol Immunopathol       Date:  2002-09-10       Impact factor: 2.046

View more
  23 in total

1.  Protein Malnutrition Alters Tryptophan and Angiotensin-Converting Enzyme 2 Homeostasis and Adaptive Immune Responses in Human Rotavirus-Infected Gnotobiotic Pigs with Human Infant Fecal Microbiota Transplant.

Authors:  David D Fischer; Sukumar Kandasamy; Francine C Paim; Stephanie N Langel; Moyasar A Alhamo; Lulu Shao; Juliet Chepngeno; Ayako Miyazaki; Huang-Chi Huang; Anand Kumar; Gireesh Rajashekara; Linda J Saif; Anastasia N Vlasova
Journal:  Clin Vaccine Immunol       Date:  2017-08-04

Review 2.  Immune responses to rotavirus infection and vaccination and associated correlates of protection.

Authors:  Ulrich Desselberger; Hans-Iko Huppertz
Journal:  J Infect Dis       Date:  2011-01-15       Impact factor: 5.226

3.  Lactobacillus acidophilus and Lactobacillus reuteri modulate cytokine responses in gnotobiotic pigs infected with human rotavirus.

Authors:  M S P Azevedo; W Zhang; K Wen; A M Gonzalez; L J Saif; A E Yousef; L Yuan
Journal:  Benef Microbes       Date:  2012-03-01       Impact factor: 4.205

4.  Viremia and nasal and rectal shedding of rotavirus in gnotobiotic pigs inoculated with Wa human rotavirus.

Authors:  M S Azevedo; L Yuan; K-I Jeong; A Gonzalez; T V Nguyen; S Pouly; M Gochnauer; W Zhang; A Azevedo; L J Saif
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

5.  Cytokine responses in gnotobiotic pigs after infection with virulent or attenuated human rotavirus.

Authors:  M S P Azevedo; L Yuan; S Pouly; A M Gonzales; K I Jeong; T V Nguyen; L J Saif
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

6.  Human milk oligosaccharides shorten rotavirus-induced diarrhea and modulate piglet mucosal immunity and colonic microbiota.

Authors:  Min Li; Marcia H Monaco; Mei Wang; Sarah S Comstock; Theresa B Kuhlenschmidt; George C Fahey; Michael J Miller; Mark S Kuhlenschmidt; Sharon M Donovan
Journal:  ISME J       Date:  2014-02-13       Impact factor: 10.302

7.  Virus-specific intestinal IFN-gamma producing T cell responses induced by human rotavirus infection and vaccines are correlated with protection against rotavirus diarrhea in gnotobiotic pigs.

Authors:  Lijuan Yuan; Ke Wen; Marli S P Azevedo; Ana M Gonzalez; Wei Zhang; Linda J Saif
Journal:  Vaccine       Date:  2008-04-18       Impact factor: 3.641

8.  Antibody responses to human rotavirus (HRV) in gnotobiotic pigs following a new prime/boost vaccine strategy using oral attenuated HRV priming and intranasal VP2/6 rotavirus-like particle (VLP) boosting with ISCOM.

Authors:  A M González; T V Nguyen; M S P Azevedo; K Jeong; F Agarib; C Iosef; K Chang; K Lovgren-Bengtsson; B Morein; L J Saif
Journal:  Clin Exp Immunol       Date:  2004-03       Impact factor: 4.330

9.  Probiotic Lactobacillus acidophilus enhances the immunogenicity of an oral rotavirus vaccine in gnotobiotic pigs.

Authors:  Wei Zhang; Marli S P Azevedo; Ke Wen; Ana Gonzalez; Linda J Saif; Guohua Li; Ahmed E Yousef; Lijuan Yuan
Journal:  Vaccine       Date:  2008-05-19       Impact factor: 3.641

10.  Sang Froid in a time of trouble: is a vaccine against HIV possible?

Authors:  Stanley A Plotkin
Journal:  J Int AIDS Soc       Date:  2009-02-02       Impact factor: 5.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.